Uptake and dose distributions in peritoneal LS174T colon tumor xenografts were compared for a humanized construct of the CC49 (HuCC49) high-affinity anti-TAG-72 monoclonal antibody and a construct with the CH2 region deleted (HuCC49DeltaCH2), both labeled with (177)Lu using a PA-DOTA bifunctional chelating agent and injected in the peritoneum. Tumors were resected and serially sectioned at 1 h, 4 h, 24 h, and 48 h postinjection. Between 5 and 24 (average 16) sections were retained per tumor for autoradiography. The typical section interval was 340 microm and thickness was 16 microm. Tumor sections were air dried and placed on film and/or phosphor screen. Section images were digitized at 100 microm resolution electronically (phosphor screen) or by laser densitometer (film). Section images were used to generate tumor surface descriptions and activity distributions by reconstructing the activity densities in three dimensions. Three-dimensional dose-rate calculations, performed using a point kernel for (177)Lu, were used to prepare radial histograms describing the variation in dose rate as a function of distance from the tumor center to surface. At early times postinjection, the (177)Lu-HuCC49DeltaCH2 antibody displayed higher dose rates near the tumor surface compared to the (177)Lu-HuCC49 antibody. At 24 h postinjection, dose rate distributions appeared similar for both antibodies and more uniform than at earlier times. The (177)Lu-HuCC49DeltaCH2 antibody indicated improved uniformity at 48 h postinjection. Cell survival calculations based on the three-dimensional dose rate distributions favored (177)Lu-HuCC49DeltaCH2 for equal injection activities. However the most significant effect was the greater injected dose tolerated for the (177)Lu-HuCC49DeltaCH2 antibody based on equivalent estimated bone marrow dose.

Download full-text PDF

Source
http://dx.doi.org/10.1089/108497803765036418DOI Listing

Publication Analysis

Top Keywords

dose rate
12
177lu-hucc49deltach2 antibody
12
three-dimensional dose
8
phosphor screen
8
tumor surface
8
rate distributions
8
dose
7
tumor
6
177lu-hucc49deltach2
5
antibody
5

Similar Publications

Background Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a highly aggressive subtype characterized by a high recurrence rate. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate targeting HER2, has shown improved outcomes; however, its effectiveness in cases with brain metastases remains unclear. The T-DM1 biosimilar has emerged as a cost-effective treatment option.

View Article and Find Full Text PDF

Background In 2024, reimbursement for gemcitabine-docetaxel therapy (GEM-DOC; gemcitabine 900 mg/m on days 1 and 8 and docetaxel 70 mg/m on day 8 every 21 days, GEM 900-DOC 70) to treat recurrent/metastatic soft tissue sarcoma (STS) was made in Japan. Methods We retrospectively reviewed clinical records of advanced/metastatic STS patients who underwent off-label gemcitabine-containing chemotherapy at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research between February 2007 and October 2019. Results Of 115 enrolled patients, 51 were treated with GEM-DOC (26 patients received the dose as previously stated) and the other 64 with gemcitabine monotherapy.

View Article and Find Full Text PDF

Introduction: We determined the median effective dose and 95% confidence interval (CI) of remimazolam required to inhibit laryngeal mask airway (LMA) insertion reactions combined with sufentanil 0.3 μg/kg in pediatric anesthesia.

Methods: Children scheduled to undergo elective laryngeal mask anesthesia were divided into the preschool (age: 3-6 years) and school-age (6-12 years) groups.

View Article and Find Full Text PDF

Background: We intended to observe the effects of different doses of remimazolam besylate via intravenous induction on the quality of sedation and cardiac function in elderly patients.

Methods: A total of 135 ASA I-III patients undergoing elective laparoscopic cholecystectomy were selected. They were divided into three groups and they were randomized.

View Article and Find Full Text PDF

Introduction: Acute fibrinous and organizing pneumonia (AFOP) is a severe form of acute lung injury which can occur after lung transplantation. Treatment is empiric, based on immunosuppressive regimens and the mortality rate is very high.

Case Presentation: We report the case of a young lung transplant (LT) recipient who developed AFOP following a respiratory viral infection while on suboptimal maintenance immunosuppression due to adherence issues.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!